Total Payments
$56,088
2024 Payments
$924.05
Companies
25
Transactions
78
Medicare Patients
874
Medicare Billing
$111,686
Payment Breakdown by Category
Consulting$36,582 (65.2%)
Other$12,560 (22.4%)
Food & Beverage$3,770 (6.7%)
Travel$3,023 (5.4%)
Education$152.53 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,582 | 14 | 65.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,560 | 2 | 18.8% |
| Food and Beverage | $3,770 | 42 | 6.7% |
| Travel and Lodging | $3,023 | 13 | 5.4% |
| Honoraria | $2,000 | 1 | 3.6% |
| Education | $152.53 | 5 | 0.3% |
| Unspecified | $0 | 1 | 0.0% |
Payments by Type
General
$56,088
77 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $21,409 | 18 | $0 (2024) |
| Amgen Inc. | $10,674 | 9 | $0 (2018) |
| Verastem, Inc. | $6,062 | 2 | $0 (2019) |
| Exelixis Inc. | $5,975 | 8 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $3,385 | 3 | $0 (2019) |
| AMAG Pharmaceuticals, Inc. | $2,937 | 6 | $0 (2018) |
| Karyopharm Therapeutics Inc. | $2,475 | 1 | $0 (2021) |
| Lilly USA, LLC | $576.84 | 2 | $0 (2024) |
| Celgene Corporation | $529.17 | 4 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $482.04 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $924.05 | 11 | Stemline Therapeutics Inc. ($299.32) |
| 2023 | $1,719 | 6 | AstraZeneca Pharmaceuticals LP ($1,383) |
| 2022 | $54.64 | 2 | AstraZeneca Pharmaceuticals LP ($54.64) |
| 2021 | $6,965 | 5 | AstraZeneca Pharmaceuticals LP ($4,453) |
| 2020 | $7,928 | 4 | AstraZeneca Pharmaceuticals LP ($7,903) |
| 2019 | $22,932 | 20 | AstraZeneca Pharmaceuticals LP ($7,335) |
| 2018 | $6,195 | 17 | AMAG Pharmaceuticals, Inc. ($2,937) |
| 2017 | $9,370 | 13 | Amgen Inc. ($8,624) |
All Payment Transactions
78 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $145.35 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: Oncology | ||||||
| 10/11/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Oncology | ||||||
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/01/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $153.97 | General |
| Category: Oncology | ||||||
| 05/18/2024 | BeiGene USA, Inc. | — | Food and Beverage | In-kind items and services | $128.62 | General |
| 05/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Oncology | ||||||
| 03/06/2024 | Genmab U.S., Inc. | — | Food and Beverage | In-kind items and services | $134.68 | General |
| 02/20/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Oncology | ||||||
| 01/23/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $94.78 | General |
| Category: Oncology | ||||||
| 11/26/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 11/20/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $146.62 | General |
| Category: Oncology | ||||||
| 05/19/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $87.86 | General |
| Category: Oncology | ||||||
| 03/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $101.12 | General |
| Category: Oncology | ||||||
| 2023 | RefleXion Medical, Inc. | — | — | — | $0.00 | Ownership |
| 11/03/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $37.09 | General |
| 05/16/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.55 | General |
| 10/27/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $4,452.50 | General |
| Category: Oncology | ||||||
| 07/23/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 05/25/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,475.00 | General |
| Category: Oncology | ||||||
| 04/06/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 222 | 383 | $92,692 | $29,708 |
| 2022 | 3 | 214 | 394 | $84,455 | $28,509 |
| 2021 | 3 | 228 | 410 | $91,723 | $32,805 |
| 2020 | 4 | 210 | 369 | $75,022 | $20,663 |
Total Patients
874
Total Services
1,556
Medicare Billing
$111,686
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 130 | $37,756 | $13,373 | 35.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 204 | $43,899 | $13,250 | 30.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $6,183 | $1,867 | 30.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 34 | $4,854 | $1,219 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 139 | 254 | $52,070 | $16,806 | 32.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 95 | $26,220 | $9,894 | 37.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 40 | 45 | $6,165 | $1,810 | 29.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 57 | 155 | $42,780 | $16,929 | 39.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 206 | $42,230 | $13,802 | 32.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 49 | $6,713 | $2,074 | 30.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 119 | 264 | $54,120 | $14,849 | 27.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 61 | 70 | $9,590 | $2,292 | 23.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 14 | 14 | $5,516 | $1,888 | 34.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 21 | $5,796 | $1,634 | 28.2% |
About Dr. Stanley Marks, M.D
Dr. Stanley Marks, M.D is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477524924.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stanley Marks, M.D has received a total of $56,088 in payments from pharmaceutical and medical device companies, with $924.05 received in 2024. These payments were reported across 78 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($36,582).
As a Medicare-enrolled provider, Marks has provided services to 874 Medicare beneficiaries, totaling 1,556 services with total Medicare billing of $111,686. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 01/31/2006
- Last Updated 01/11/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1477524924
Products in Payments
- CALQUENCE (Drug) $13,879
- Copiktra (Drug) $6,062
- Cabozantinib (Drug) $5,801
- PROVENGE (Drug) $3,385
- FERAHEME (Drug) $2,937
- XPOVIO (Drug) $2,475
- XGEVA (Biological) $823.73
- KEYTRUDA (Biological) $482.04
- Orserdu (Drug) $445.94
- ADCETRIS (Biological) $208.98
- CABOMETYX (Drug) $174.00
- DARZALEX (Biological) $138.56
- Vectibix (Biological) $119.79
- BRUKINSA (Drug) $107.51
- Imbruvica (Drug) $99.99
- BELEODAQ (Drug) $37.87
- VERZENIO (Drug) $26.84
- NERLYNX (Drug) $25.18
- CINVANTI (Drug) $15.10
- VALCHLOR MECHLORETHAMINE (Drug) $14.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Dr. Alexander Barsouk, Md, MD
Hematology & Oncology — Payments: $905,454
Hematology & Oncology $905,454
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Dr. Jason Luke, M.d, M.D
Hematology & Oncology — Payments: $431,360
Hematology & Oncology $431,360